The pope has recovered from surgery to remove part of his lung, so what caused his illness, and how likely is he to recover?

Oct 13 (Reuters) - BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of ...

While PFS was not achieved in BioNTech’s cancer vaccine trial, there is still a chance for success with OS.

Head and neck squamous cell carcinoma (HNSCC) frequently develops in the oral and upper aerodigestive regions following ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

BioNTech shares fell more than 5% after the company reported that its mRNA cancer immunotherapy BNT113, combined with Merck's ...

BioNTech Shares Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy in Metastatic HPV16-Positive HNC / ...

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...

BioNTech's BNT113 missed progression-free survival in an HPV-linked head and neck cancer trial; study continues to test ...

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy ...

A prospective study of 95,612 U.S. adults found that those with the highest sulfur microbial diet scores had a 23% higher ...

BioNTech's BNT113 misses Phase III PFS endpoint in HPV16-positive head and neck cancer. Read the full trial update and what ...